Research Article
[Retracted] Clinical Evaluation of Levetiracetam in the Treatment of Epilepsy
Table 2
Treatment effect statistics in each group.
| | Group | Successful symptom control/case | Average real time of successful control/cases | Recurrence of symptoms/cases | Recurrence time/min | Adverse reaction/case | Abnormal EEG discharge/case |
| | Sodium valproate control group | 39 (65.0%) | 124 | 16 (41.0%) | 115 | 8 (13.3%) | 26 (43.3%) | | 500 mg/d levetiracetam | 18 (52.9%) | 104 | 12 (66.6%) | 153 | 0 | 18 (52.9%) | | 1000 mg/d levetiracetam | 42 (77.7%) | 70 | 13 (30%) | 260 | 3 (7.2%) | 14 (33.3%) | | 1500 mg/d levetiracetam | 20 (80.0%) | 83 | 4 (20%) | 204 | 6 (24%) | 5 (20.0%) |
|
|
Compared with the control group, . |
